Viveve Medical (NASDAQ:VIVE)‘s stock had its “buy” rating restated by stock analysts at Mizuho in a report issued on Friday. They currently have a $10.00 price objective on the stock. Mizuho’s target price points to a potential upside of 101.21% from the stock’s previous close.

VIVE has been the topic of a number of other reports. Cowen set a $11.00 price objective on shares of Viveve Medical and gave the company a “buy” rating in a research note on Monday, October 23rd. Northland Securities began coverage on shares of Viveve Medical in a research note on Friday. They issued an “outperform” rating and a $8.00 price objective on the stock. Finally, ValuEngine cut shares of Viveve Medical from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Viveve Medical presently has a consensus rating of “Buy” and a consensus price target of $10.00.

Shares of Viveve Medical (VIVE) traded down $0.22 during midday trading on Friday, reaching $4.97. 250,000 shares of the company were exchanged, compared to its average volume of 138,267. The firm has a market cap of $96.55, a PE ratio of -2.31 and a beta of -0.67. Viveve Medical has a 12-month low of $3.75 and a 12-month high of $11.16. The company has a debt-to-equity ratio of 2.72, a quick ratio of 3.63 and a current ratio of 3.89.

Viveve Medical (NASDAQ:VIVE) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.50) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.08). The business had revenue of $4.07 million during the quarter, compared to analyst estimates of $4.10 million. Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. Viveve Medical’s revenue was up 120.1% on a year-over-year basis. During the same period in the previous year, the company posted ($0.46) earnings per share. analysts predict that Viveve Medical will post -2.04 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers acquired a new stake in shares of Viveve Medical during the 2nd quarter worth about $110,000. JPMorgan Chase & Co. acquired a new stake in shares of Viveve Medical during the 2nd quarter worth about $151,000. Virtu KCG Holdings LLC acquired a new stake in shares of Viveve Medical during the 2nd quarter worth about $169,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Viveve Medical during the 2nd quarter worth about $189,000. Finally, California State Teachers Retirement System acquired a new stake in shares of Viveve Medical during the 2nd quarter worth about $190,000. 66.90% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.americanbankingnews.com/2018/01/05/viveve-medical-vive-given-buy-rating-at-mizuho.html.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.